Eisai is a research-based human health care company which discovers, develops, packages, and markets pharmaceutical products with focus on neurology, oncology, Alzheimer's disease, epilepsy, and metabolic disorders. It offers a portfolio of tablets and injections for treatment of various diseases. The Company‘s areas of research and development focus include neuroscience, oncology, vascular, inflammatory and immunological reaction, and antibody-based programs.

Type
Public
HQ
Woodcliff Lake, US
Founded
1941
Size (employees)
10,495 (est)
Eisai was founded in 1941 and is headquartered in Woodcliff Lake, US
Report incorrect company information

Eisai Office Locations

Eisai has an office in Woodcliff Lake
Woodcliff Lake, US (HQ)
100 Tice Blvd
Show all (1)
Report incorrect company information

Eisai Financials and Metrics

Eisai Financials

Market capitalization (31-Oct-2017)

15.9 b

Closing share price (31-Oct-2017)

55.3
Eisai's current market capitalization is $15.9 b.
Show all financial metrics
Report incorrect company information

Eisai News and Updates

Histone Methyltransferases Market - New Era Of Industry & Forecast 2013 - 2019

Transparency Market Research offers meticulously researched market studies backed by 4 million hours of research experience. Currently handling over 350 client queries each day, it covers over 60 countries around the world. Also, 1.2 million data points are captured each year. Posted via Industry T…

Donepezil Market will grow in the upcoming year with Leading Key players Eisai, Pfizer, Teva, Sandoz, etc.

The qualitative research study conducted by HTF MI titled “North America and Europe Donepezil Market by Manufacturers, Regions, Type and Application, Forecast to 2023” provides primary Data, surveys, Scope of the Product and vendor briefings. Posted via Industry Today. Follow us on Twitter @Industr…

FiercePharmaAsia—Merck-Eisai’s Lenvima deal, JW’s $90M series A, novel HIV drug

Merck signed a deal potentially worth $5.8 billion for half of Lenvima's sales; Juno and WuXi AppTec's CAR-T joint venture got $90 million in a series A; the FDA approved TaiMed Biologics’ novel HIV drug Trogarzo manufactured by WuXi Biologics; plus more pharma industry news from Asia.

In another blockbuster cancer deal, Merck lays out up to $5.8B for half of Eisai's Lenvima

Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.

Insomnia Medication Market increasing demand with Leading key players: Eisai, Merck, Pfizer, Sanofi, Takeda

HTF MI published a new industry research that focuses on Insomnia Medication market and delivers in-depth market analysis and future prospects of China Insomnia Medication market. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information